Ikarian Capital’s Ascendis Pharma A/S ASND Stock Holding History

Ikarian Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,400	Closed	-$1.34M	–	192
2021 Q3	$1.34M	Sell	8,400 -200	-2%	-$27.4K	0.09%	146
2021 Q2	$1.13M	Sell	8,600 -42,100	-83%	-$5.61M	0.09%	153
2021 Q1	$6.53M	Hold	50,700	–	–	0.22%	101
2020 Q4	$8.46M	Sell	50,700 -94,300	-65%	-$15.6M	0.37%	65
2020 Q3	$22.4M	Hold	145,000	–	–	1.62%	13
2020 Q2	$21.4M	Buy	+145,000	New	+$19.9M	1.71%	10
2020 Q1	–	Sell	-69,400	Closed	-$9.65M	–	159
2019 Q4	$9.65M	Buy	+69,400	New	+$7.71M	1.56%	15

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's ASND Position: Q3 2023 in Review

Ikarian Capital sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 2,090 shares — an estimated $187K sold.

Ikarian Capital first reported a position in ASND in Q4 2020 and held it in 6 quarters. The position peaked at $14.5M in Q4 2020. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

Ikarian Capital reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 2,090 Ascendis Pharma A/S shares in Q3 2023, an estimated $187K.
Ikarian Capital first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 6 quarters.
Ikarian Capital's Ascendis Pharma A/S position peaked at $14.5M in Q4 2020.
160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.